4/A: Celularity Director Peter Diamandis Increases Stake

Celularity Inc. Director Peter Diamandis reported an amended acquisition of 20,385 Class A common stock shares through immediately vesting restricted stock units.

Summary

• Peter Diamandis, a Director of Celularity Inc. (CELU), reported an acquisition of 20,385 shares of Class A Common Stock.
• The transaction occurred on January 12, 2026, and was an amendment to an original filing on January 14, 2026.
• These shares represent Restricted Stock Units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU represents a right to receive one share of the Issuer's Class A common stock, and the RSUs vested immediately upon grant.
• The acquisition price for these RSUs was $0.00.
• Following this transaction, Peter Diamandis beneficially owns a total of 394,150 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, even through a grant, generally signals continued alignment of interests with shareholders and confidence in the company's future. The immediate vesting is also a positive sign.

Positives

• A Director, Peter Diamandis, increased his beneficial ownership in Celularity Inc. by 20,385 shares.
• The shares were granted as Restricted Stock Units (RSUs) which vested immediately, indicating a direct and immediate increase in his stake.
• The transaction was made pursuant to a Rule 10b5-1 plan, suggesting a pre-arranged and systematic approach to equity transactions.

Negatives

• The shares were acquired at a price of $0.00, indicating they were a grant rather than an open market purchase, which might be seen as less of a direct vote of confidence compared to a cash purchase.

Risks

• No specific risks are detailed in this Form 4/A filing, as it primarily reports an insider transaction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape. However, insider grants are common compensation practices in the biotechnology and healthcare sectors, where Celularity operates.

Related Party Transactions

• The grant of 20,385 Restricted Stock Units to Peter Diamandis, a Director, under the Celularity Inc. 2021 Equity Incentive Plan, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's increased stake as a positive signal, indicating management's continued commitment and belief in the company's prospects.
• Employees: No direct impact mentioned, but equity grants are a common part of compensation structures.
• Management: The transaction reflects the ongoing equity compensation strategy for directors.

Key Dates

Recommendation

While the increase in a director's beneficial ownership through an RSU grant is generally a positive signal of alignment, a single Form 4/A filing, especially for a compensation-related grant rather than an open-market purchase, typically does not provide sufficient information to warrant a strong 'buy' or 'sell' recommendation. It reinforces a 'hold' position for investors who are already invested, as it indicates continued insider confidence without revealing new fundamental catalysts.

Keywords

Celularity Inc., CELU, Peter Diamandis, Insider Transaction, Form 4/A, Restricted Stock Units, RSU, Equity Incentive Plan, Director, Beneficial Ownership